Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

/PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S....

Related Keywords

Kentucky ,United States ,Japan ,Minnesota ,Israel ,Pikeville ,Gina Wesley ,Richard Lindstrom ,Elad Kedar ,Sheri Rowen ,Amy Phillips ,Paul Smith ,Paul Karpecki ,Orasis Pharmaceuticals ,Sequoia Capital ,Drug Administration ,Prnewswire Orasis Pharmaceuticals ,Kentucky College Of Optometry ,Japan Innovation Fund ,Kentucky Eye Institute ,Linkedin ,Nvision Eye Centers ,University Of Pikeville ,Chief Executive Officer ,External Disease ,Associate Professor ,Kentucky College ,Medical Director ,Eye Centers ,Newport Beach ,Full Prescribing Information ,Chief Operating Officer ,Complete Eye Care ,Attending Surgeon Emeritus ,Minnesota Eye ,Visionary Ventures ,Innovation Fund ,Bluestem Capital ,Lifesci Venture Partners ,Maverick Ventures Israel ,Important Safety ,